
About Synthetic Biologics
Synthetic Biologics is a Healthcare company based in Rockville (United States) founded in 1986. Developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The company has 21 employees. Its chief executive, as recorded, is Steven Shallcross. Synthetic Biologics offers products and services including Oncolytic Viruses, SYN-004, and VCN-01. Its focus areas include Life Sciences, Microbiome Therapeutics, Targeted Agents and Infectious Diseases. Its legal entity is SYNTHETIC BIOLOGICS, INC. Similar companies include Amyris, Kriya Therapeutics and Pivot Bio; 3 of its 3 listed similar companies have raised funding.
Company details
Founded in 1986 and headquartered in Rockville, United States, Synthetic Biologics operates as a clinical-stage company in the synthetic biology sector. Therapeutics are developed to safeguard the gut microbiome from intravenous beta-lactam antibiotics, aiming to prevent C. difficile infections and antibiotic-associated diarrhea through SYN-004. SYN-010 is advanced to address methane-producing organisms in IBS-C. Preclinical monoclonal antibodies for pertussis and biotherapeutics for phenylketonuria are pursued in collaboration with Intrexon Corporation.
- Headquarters Rockville, United States
- Employees 21
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website syntheticbiologics.com
- Social LinkedIn X Facebook
- Legal Name Synthetic Biologics, Inc.
- Annual Revenue$2.61 M (USD)as on Dec 31, 2010
- Net Profit-$14.27 M (USD)-42as on Dec 31, 2021
- EBITDA-$14.27 M (USD)-40as on Dec 31, 2021
- Latest Funding Round$3M (USD), Post-IPO
Jul 2022
- Employee Count21
Products & Services of Synthetic Biologics
Synthetic Biologics offers a comprehensive portfolio of products and services, including Oncolytic Viruses, SYN-004, and VCN-01.
Engineered viruses to selectively destroy tumor cells.
Targets protection in hematopoietic cell transplant recipients.
Combines with chemotherapy for metastatic pancreatic cancer.
Funding Insights of Synthetic Biologics
- Total Rounds 4
- Last Round Post-IPO β $3M
- First Round $10.8M
(Nov 2012)
All 4 funding rounds of Synthetic Biologics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2022 | $3M | Post-IPO | β | β | β |
| Sep 2017 | $12M | Post-IPO | β | β | β |
| Sep 2013 | $5.61M | Grant | β | β | β |
| Nov 2012 | $10.8M | Post-IPO | β | β | β |
People of Synthetic Biologics
1 people are tracked at Synthetic Biologics (1 in leadership); the tracked headcount is 21.
| Name | Role | Group |
|---|---|---|
Steven Shallcross | CEO | Leadership |
Complete people profiles for Synthetic Biologics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Synthetic Biologics
3 dated milestones of Synthetic Biologics across 36 years, from founding to its latest funding, stage changes and deals.
- Founded Synthetic Biologics is founded.
- Funding First funding round of $10.8M.
- Funding Latest funding round, Post-IPO, of $3.0M.
Similar companies to Synthetic Biologics
Synthetic Biologics has 3 listed similar companies in our database, 3 of them funded. They include Amyris, Kriya Therapeutics and Pivot Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| amyris.com | 2003 | Emeryville, United States | $487.2M | 747 | Developer of renewable products for industrial solutions | |
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| pivotbio.com | 2010 | Berkeley, United States | $618.08M | 256 | Nitrogen-fixing microbes for corn crop nutrition are developed and applied. |
Detailed similar companies of Synthetic Biologics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Synthetic Biologics
Websites that share an audience with Synthetic Biologics (syntheticbiologics.com).
Websites whose visitors overlap most with Synthetic Biologics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| tgtherapeutics.com | 100% | 29.4K | #1,758,849 | View details | |
nacfconference.org | nacfconference.org | 68% | #3,847,203 | β |
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Synthetic Biologics (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Synthetic Biologics
Complete news archive for Synthetic Biologics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Synthetic Biologics
Synthetic Biologics was founded in 1986 and raised its 1st funding round 26 years after it was founded.
Synthetic Biologics is headquartered in Rockville, United States. It is registered at Rockville, Maryland, United States.
Steven Shallcross is the CEO of Synthetic Biologics, as recorded in our data.
Synthetic Biologics has 21 employees.
Annual revenue of Synthetic Biologics is $2.61M as on Dec 31, 2010.
Founded in 1986 and headquartered in Rockville, United States, Synthetic Biologics operates as a clinical-stage company in the synthetic biology sector. Therapeutics are developed to safeguard the gut microbiome from intravenous beta-lactam antibiotics, aiming to prevent C. difficile infections and antibiotic-associated diarrhea through SYN-004. SYN-010 is advanced to address methane-producing organisms in IBS-C. Preclinical monoclonal antibodies for pertussis and biotherapeutics for phenylketonuria are pursued in collaboration with Intrexon Corporation.
Synthetic Biologics's top competitors include Amyris, Pivot Bio and Kriya Therapeutics.
Synthetic Biologics offers Oncolytic Viruses, SYN-004, and VCN-01.
Synthetic Biologics operates through Synthetic Biologics, Inc..
